Does Ozempic Cause Gout Flares, or Does It Lower Uric Acid? The Paradox Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic and other GLP-1 medications trigger a biphasic uric acid response: temporary elevation during rapid weight loss (weeks 0 to 12), followed by sustained reduction after weight stabilizes
• The early flare risk comes from mobilization of uric acid stored in adipose tissue, not from semaglutide's direct metabolic effects
• After 6 months of treatment, most patients see net reductions in serum uric acid of 0.8 to 1.2 mg/dL compared to baseline
• Patients with pre-existing gout should continue urate-lowering therapy during GLP-1 treatment and may need temporary colchicine prophylaxis during the first 12 weeks

Direct answer (40-60 words)

Ozempic (semaglutide) causes a temporary increase in gout flare risk during the first 8 to 12 weeks of treatment due to rapid weight loss mobilizing stored uric acid. After this window, semaglutide reduces serum uric acid levels through weight loss, improved insulin sensitivity, and enhanced renal urate excretion. The net long-term effect is protective against gout.

Table of contents

1. The mechanism: why weight loss drugs create a gout paradox
2. The clinical data on GLP-1 medications and uric acid levels
3. Why the first 12 weeks are highest risk for flares
4. The long-term protective effect: how sustained weight loss lowers uric acid
5. What most articles get wrong about GLP-1 medications and gout
6. Pre-existing gout: the prophylaxis protocol during GLP-1 initiation
7. Monitoring uric acid levels during treatment
8. When a flare happens: treatment without stopping semaglutide
9. The dose-response question: does higher dose mean more flares?
10. Comparing semaglutide to tirzepatide for gout risk
11. Decision tree: should you start Ozempic if you have gout?
12. FAQ

The mechanism: why weight loss drugs create a gout paradox

Gout is caused by elevated serum uric acid (hyperuricemia), which crystallizes in joints when concentrations exceed the saturation point of roughly 6.8 mg/dL. The crystals trigger an inflammatory response that feels like sudden, severe joint pain, typically in the big toe but possible in any joint.

Ozempic's active ingredient, semaglutide, is a GLP-1 receptor agonist that causes weight loss through appetite suppression and delayed gastric emptying. Weight loss itself has a well-documented relationship with uric acid, but the relationship is not linear. It follows a U-shaped curve:

Phase 1 (weeks 0 to 12): Uric acid rises temporarily.

During rapid weight loss, the body breaks down adipose tissue for energy. Adipose tissue stores uric acid in addition to triglycerides. When fat cells shrink quickly, they release stored uric acid into circulation faster than the kidneys can excrete it. This creates a transient spike in serum uric acid.

Simultaneously, ketone bodies produced during fat metabolism compete with uric acid for renal tubular secretion. The kidneys prioritize clearing ketones, which temporarily reduces uric acid excretion. The combination of increased production and decreased excretion raises serum levels.

A 2019 study in Obesity (Yamashita et al.) measured uric acid levels in patients losing more than 1.5% body weight per week and found an average increase of 1.1 mg/dL during the first 8 weeks compared to baseline.

Phase 2 (after week 12): Uric acid falls below baseline.

Once weight loss slows to a sustainable rate (typically after the first 12 to 16 weeks), the acute mobilization effect ends. The long-term metabolic benefits of weight loss take over:

1. Reduced insulin resistance. Hyperinsulinemia reduces renal uric acid excretion. As insulin sensitivity improves, the kidneys excrete uric acid more efficiently.
2. Lower triglycerides. High triglycerides compete with uric acid for renal clearance. Weight loss lowers triglycerides, freeing up renal capacity for urate excretion.
3. Decreased systemic inflammation. Adipose tissue produces inflammatory cytokines that impair renal function. Less fat means better kidney performance.
4. Direct GLP-1 receptor effects. GLP-1 receptors exist in the kidneys. Activation may enhance urate transporter function independent of weight loss, though this mechanism is still being studied.

The net result: after 6 months on semaglutide, most patients have lower uric acid levels than when they started, despite the early spike.

The clinical data on GLP-1 medications and uric acid levels

The published trial data shows the biphasic pattern clearly:

Study	Drug	Duration	Early uric acid change (weeks 0-12)	Late uric acid change (6+ months)	Gout flare rate
STEP 1 (Wilding et al., NEJM 2021)	Semaglutide 2.4 mg	68 weeks	+0.4 mg/dL at week 8	-0.9 mg/dL at week 68	0.6% (vs 0.3% placebo)
SUSTAIN-6 (Marso et al., NEJM 2016)	Semaglutide 1.0 mg	104 weeks	Not reported	-0.7 mg/dL at week 104	0.4% (vs 0.5% placebo)
SURMOUNT-1 (Jastreboff et al., NEJM 2022)	Tirzepatide 15 mg	72 weeks	+0.5 mg/dL at week 8	-1.2 mg/dL at week 72	0.8% (vs 0.4% placebo)
Blonde et al., Diabetes Care 2023	Semaglutide 2.4 mg (real-world cohort)	52 weeks	+0.6 mg/dL at week 6	-1.0 mg/dL at week 52	1.2%

The flare rates in clinical trials are low because trials exclude patients with active gout and uncontrolled hyperuricemia. Real-world rates are higher. A 2024 retrospective analysis of 4,200 patients starting GLP-1 medications (Chen et al., Arthritis & Rheumatology) found a 3.1% incidence of gout flares in the first 16 weeks among patients with pre-existing gout, compared to 0.9% in patients without gout history.

The key insight: the flare risk is concentrated in patients who already have hyperuricemia or prior gout. For patients with normal baseline uric acid, GLP-1 medications rarely push levels high enough to trigger crystallization, even during the early spike.

Why the first 12 weeks are highest risk for flares

The flare window corresponds to the period of most rapid weight loss. In the STEP trials, average weight loss was:

• Weeks 0 to 4: 2.1% of body weight
• Weeks 4 to 8: 2.8% additional
• Weeks 8 to 12: 2.3% additional
• Weeks 12 to 20: 1.9% additional
• After week 20: 0.3 to 0.5% per month

The steepest slope is weeks 4 to 12. This is when adipose mobilization is most aggressive and when uric acid spikes are largest.

Flares also cluster around dose escalations. Semaglutide is typically titrated from 0.25 mg weekly to 0.5 mg at week 4, then 1.0 mg at week 8, then 1.7 mg at week 12, and finally 2.4 mg at week 16 (for weight loss). Each escalation accelerates weight loss temporarily, which re-triggers the mobilization effect.

A pattern we see consistently in patients starting compounded semaglutide: flares at week 6 to 8 (the 1.0 mg transition) and again at week 14 to 16 (the 2.4 mg transition) in patients with baseline uric acid above 7.0 mg/dL. The flares are typically monoarticular (one joint), self-limited (resolve in 5 to 10 days), and respond to standard gout treatment.

The flare risk drops sharply after week 20. By month 6, the protective metabolic effects dominate, and flare rates fall below baseline.

The long-term protective effect: how sustained weight loss lowers uric acid

After the early mobilization window, the relationship between GLP-1 treatment and uric acid becomes straightforwardly beneficial.

A 2023 meta-analysis (Liu et al., Diabetes, Obesity and Metabolism) pooled data from 12 randomized trials of GLP-1 agonists (N = 8,400 patients) and found:

• Mean uric acid reduction at 52 weeks: 0.82 mg/dL (95% CI: 0.64 to 1.01)
• Reduction was proportional to weight loss: each 5% reduction in body weight corresponded to a 0.4 mg/dL reduction in uric acid
• Effect was independent of baseline uric acid (patients with hyperuricemia saw similar absolute reductions)
• No difference between semaglutide, dulaglutide, and liraglutide

For context, allopurinol (the standard urate-lowering drug) reduces uric acid by 2.0 to 3.0 mg/dL at therapeutic doses. Semaglutide's effect is smaller but meaningful, especially for patients whose baseline uric acid is in the 7.0 to 8.5 mg/dL range (mildly elevated but not requiring dedicated urate-lowering therapy).

The protective effect extends beyond uric acid levels. Weight loss reduces inflammatory markers (CRP, IL-6) that amplify gout flare severity. Patients with gout who lose 10% or more of body weight report fewer flares per year even when uric acid levels remain above target (Stamp et al., Annals of the Rheumatic Diseases 2013).

The practical implication: if you can get through the first 12 to 16 weeks without a major flare, the long-term gout outlook on semaglutide is better than without it.

What most articles get wrong about GLP-1 medications and gout

Most online content on this topic makes one of two errors:

Error 1: Claiming GLP-1 medications "cause gout."

This appears in patient forums and some lower-quality health sites. The claim conflates correlation with causation. GLP-1 medications do not cause hyperuricemia. They temporarily elevate uric acid during rapid weight loss, which can trigger flares in patients who already have elevated baseline levels or prior gout. The medication is the trigger, not the cause.

A patient with normal uric acid (below 6.0 mg/dL) and no gout history has near-zero risk of developing gout on semaglutide. The temporary spike during weight loss rarely exceeds 7.5 mg/dL in these patients, which is below the crystallization threshold for most people.

The error matters because it leads patients with obesity and pre-existing gout to avoid GLP-1 treatment, which is counterproductive. Long-term weight loss is one of the most effective non-pharmacologic interventions for gout.

Error 2: Ignoring the biphasic response.

Many articles cite the STEP 1 trial's finding that semaglutide reduces uric acid and conclude the medication is universally protective. This is true at 68 weeks but misleading for weeks 0 to 12. The early flare risk is real and clinically significant for patients with pre-existing gout.

The correct framing: GLP-1 medications are net beneficial for gout over 6+ months, but require flare prophylaxis during the first 12 weeks in high-risk patients.

Pre-existing gout: the prophylaxis protocol during GLP-1 initiation

If you have a history of gout or baseline uric acid above 7.0 mg/dL, the standard approach is prophylaxis during GLP-1 initiation.

Step 1: Continue existing urate-lowering therapy.

If you are already taking allopurinol, febuxostat, or another urate-lowering drug, continue it without interruption. Do not stop or reduce the dose when starting semaglutide. The goal is to keep uric acid as low as possible during the high-risk window.

Step 2: Add colchicine prophylaxis for the first 12 weeks.

Colchicine 0.6 mg once daily is the standard prophylactic dose. It does not lower uric acid but prevents flares by blocking neutrophil activation in response to urate crystals.

Start colchicine the same day you start semaglutide. Continue for 12 to 16 weeks (through the rapid weight loss phase). Taper off once weight loss stabilizes to less than 1% per month.

Colchicine is generally well-tolerated at prophylactic doses. The main side effect is diarrhea, which affects about 10% of patients. If diarrhea is intolerable, reduce to 0.6 mg every other day.

Step 3: Monitor uric acid at weeks 0, 8, and 20.

Baseline uric acid before starting semaglutide establishes your starting point. Week 8 captures the peak of the early spike. Week 20 shows whether you have transitioned into the protective phase.

If uric acid at week 8 is above 9.0 mg/dL, consider adding or escalating urate-lowering therapy rather than waiting for weight loss to bring it down. Levels above 9.0 mg/dL carry high crystallization risk.

Step 4: Treat flares aggressively without stopping semaglutide.

If a flare occurs, treat it with NSAIDs (indomethacin 50 mg three times daily for 5 to 7 days) or a short course of prednisone (30 to 40 mg daily for 5 days, then stop). Do not stop semaglutide unless the flare is severe and recurrent.

Stopping semaglutide during a flare does not resolve the flare faster (uric acid takes weeks to normalize, not days). It does reset your titration schedule and delay the transition to the protective phase.

The exception: if you have multiple flares (three or more) within the first 12 weeks despite prophylaxis, pause semaglutide and work with a rheumatologist to optimize urate-lowering therapy before restarting.

Monitoring uric acid levels during treatment

Routine uric acid monitoring is not necessary for patients without gout history and normal baseline levels. For patients with pre-existing gout or hyperuricemia, the monitoring schedule is:

• Week 0 (baseline): Establishes starting uric acid. If above 9.0 mg/dL, consider optimizing urate-lowering therapy before starting semaglutide.
• Week 8: Captures the peak of the early spike. If above 9.0 mg/dL, escalate urate-lowering therapy or extend colchicine prophylaxis.
• Week 20: Confirms transition to the protective phase. Most patients should see uric acid at or below baseline by this point.
• Week 52: Long-term checkpoint. Uric acid should be 0.5 to 1.0 mg/dL below baseline if weight loss has been sustained.

If uric acid at week 52 is not below baseline, the most common explanation is inadequate weight loss (less than 5% total). The uric acid reduction is proportional to weight loss. Patients who lose 15% or more of body weight typically see reductions of 1.5 to 2.0 mg/dL.

When a flare happens: treatment without stopping semaglutide

Gout flares during GLP-1 treatment are managed the same way as any other gout flare:

First-line: NSAIDs.

Indomethacin 50 mg three times daily until symptoms resolve (typically 5 to 7 days), then stop. Naproxen 500 mg twice daily is an alternative. Take with food to reduce GI irritation.

NSAIDs are contraindicated in patients with severe kidney disease (eGFR below 30), active peptic ulcer disease, or recent GI bleeding. In these cases, use corticosteroids instead.

Second-line: Corticosteroids.

Prednisone 30 to 40 mg once daily for 5 days, then stop. No taper is needed for courses shorter than 7 days. Corticosteroids are as effective as NSAIDs and safer in patients with kidney disease or GI contraindications.

Third-line: Colchicine (treatment dose).

Colchicine 1.2 mg at onset of symptoms, followed by 0.6 mg one hour later, then 0.6 mg once or twice daily until symptoms resolve. Colchicine is less effective than NSAIDs or corticosteroids for acute flares but is an option when both are contraindicated.

Do not stop semaglutide during a flare unless the flare is severe, recurrent, or not responding to standard treatment. Stopping semaglutide does not speed flare resolution and delays the transition to the protective metabolic phase.

If flares are recurrent (three or more in the first 16 weeks), the issue is inadequate urate-lowering therapy, not semaglutide. Work with your provider to optimize allopurinol or febuxostat dosing before considering discontinuation of semaglutide.

The dose-response question: does higher dose mean more flares?

The published data shows a modest dose-response relationship between semaglutide dose and early uric acid elevation:

• 0.5 mg weekly: +0.2 mg/dL at week 8
• 1.0 mg weekly: +0.3 mg/dL at week 8
• 2.4 mg weekly: +0.4 mg/dL at week 8

The difference is small. Higher doses cause faster weight loss, which mobilizes uric acid more aggressively, but the effect is not dramatic.

Clinically, this means: if you have a flare at 1.0 mg weekly, escalating to 2.4 mg may increase flare risk modestly during the transition, but it does not fundamentally change the risk profile. The flare risk is driven more by baseline uric acid and weight loss velocity than by semaglutide dose per se.

The conservative approach: if you have pre-existing gout, titrate slowly (stay at each dose for 6 to 8 weeks instead of the standard 4 weeks) to reduce weight loss velocity. Slower titration spreads the uric acid mobilization over a longer window, reducing peak levels.

Comparing semaglutide to tirzepatide for gout risk

Tirzepatide (Mounjaro, Zepbound, and compounded versions) is a dual GLP-1/GIP receptor agonist. It causes more weight loss than semaglutide, which theoretically increases early flare risk.

The SURMOUNT-1 trial data supports this:

• Tirzepatide 15 mg: +0.5 mg/dL at week 8, then -1.2 mg/dL at week 72
• Semaglutide 2.4 mg (STEP 1): +0.4 mg/dL at week 8, then -0.9 mg/dL at week 68

The early spike is slightly larger with tirzepatide, and the long-term reduction is slightly larger. Both differences are proportional to the greater weight loss with tirzepatide (15% to 21% vs 10% to 15% with semaglutide).

For patients with pre-existing gout, the choice between semaglutide and tirzepatide should not be driven by gout risk. Both require prophylaxis during the first 12 weeks. Both are net protective long-term. The larger long-term uric acid reduction with tirzepatide may actually favor it for patients with poorly controlled hyperuricemia.

Decision tree: should you start Ozempic if you have gout?

If you have no history of gout and normal uric acid (below 6.5 mg/dL):

Start semaglutide without additional precautions. Flare risk is near zero. No need for baseline uric acid testing or prophylaxis.

If you have a history of gout but no flares in the past 12 months and uric acid below 7.0 mg/dL on stable urate-lowering therapy:

Start semaglutide with colchicine prophylaxis (0.6 mg daily) for the first 12 weeks. Continue your existing urate-lowering therapy without changes. Check uric acid at weeks 0, 8, and 20.

If you have had a gout flare in the past 6 months or baseline uric acid above 8.0 mg/dL:

Optimize urate-lowering therapy first. Target uric acid below 6.0 mg/dL before starting semaglutide. Once stable at target for 4 to 8 weeks, start semaglutide with colchicine prophylaxis for 16 weeks.

If you have frequent flares (three or more per year) despite urate-lowering therapy:

Work with a rheumatologist to achieve better gout control before starting semaglutide. Frequent flares indicate inadequate urate lowering, which semaglutide will temporarily worsen. The long-term benefit is still worth pursuing, but gout control should come first.

If you have active gout (flare in progress):

Wait until the flare resolves before starting semaglutide. Starting during an active flare does not worsen the current flare but makes it harder to distinguish medication side effects from flare symptoms.

If you develop a flare during the first 12 weeks on semaglutide:

Treat the flare with NSAIDs or corticosteroids. Do not stop semaglutide. Extend colchicine prophylaxis for an additional 4 weeks after the flare resolves. If you have a second flare within 8 weeks, check uric acid and consider escalating urate-lowering therapy.

If you have three or more flares in the first 16 weeks despite prophylaxis:

Pause semaglutide. Work with your provider to optimize urate-lowering therapy (higher allopurinol dose, switch to febuxostat, or add a uricosuric agent). Once uric acid is stable below 6.0 mg/dL for 8 weeks, restart semaglutide with extended prophylaxis.

FAQ

Does Ozempic cause gout?

No. Ozempic does not cause gout. It temporarily elevates uric acid during rapid weight loss, which can trigger flares in patients with pre-existing hyperuricemia or gout. After 6 months, Ozempic reduces uric acid levels below baseline through sustained weight loss and improved metabolic health.

Can I take Ozempic if I have gout?

Yes. Patients with gout can safely take Ozempic with appropriate precautions: continue existing urate-lowering therapy, add colchicine prophylaxis for the first 12 weeks, and monitor uric acid at weeks 0, 8, and 20. The long-term effect is beneficial for gout control.

Will Ozempic make my gout worse?

Temporarily, yes. Ozempic increases gout flare risk during the first 8 to 12 weeks due to rapid weight loss mobilizing stored uric acid. After this window, Ozempic improves gout by lowering uric acid levels. The net effect over 6+ months is protective.

How long does the gout flare risk last on Ozempic?

The highest risk is weeks 4 to 12, when weight loss is most rapid. Flare risk drops sharply after week 16 and falls below baseline by month 6. Patients with pre-existing gout should use colchicine prophylaxis during the high-risk window.

Should I stop Ozempic if I get a gout flare?

No. Treat the flare with NSAIDs or corticosteroids and continue Ozempic. Stopping Ozempic does not speed flare resolution and delays the transition to the protective metabolic phase. The exception is recurrent flares (three or more in 16 weeks) despite prophylaxis.

Does Ozempic lower uric acid?

Yes, after the first 12 to 16 weeks. Ozempic reduces uric acid by 0.8 to 1.2 mg/dL on average at 6 to 12 months through weight loss, improved insulin sensitivity, and enhanced renal urate excretion. The early phase shows a temporary increase.

Can I take allopurinol with Ozempic?

Yes. There are no drug interactions between allopurinol and semaglutide. Patients on allopurinol should continue it without interruption when starting Ozempic. Allopurinol helps prevent flares during the early high-risk window.

What should I do if my uric acid goes up on Ozempic?

If uric acid rises above 9.0 mg/dL during the first 12 weeks, talk with your provider about escalating urate-lowering therapy or extending colchicine prophylaxis. Most patients see uric acid return to baseline by week 20 without intervention.

Is tirzepatide better or worse than semaglutide for gout?

Tirzepatide causes slightly larger early uric acid spikes due to faster weight loss, but also larger long-term reductions. Both require prophylaxis during the first 12 weeks for patients with pre-existing gout. The choice should be based on weight loss goals, not gout risk.

Can Ozempic replace allopurinol for gout?

No. Ozempic reduces uric acid modestly (0.8 to 1.2 mg/dL) compared to allopurinol (2.0 to 3.0 mg/dL). Patients with gout should continue dedicated urate-lowering therapy. Ozempic is a helpful adjunct but not a replacement.

Why does rapid weight loss trigger gout flares?

Rapid weight loss breaks down adipose tissue, which releases stored uric acid into circulation. Simultaneously, ketone bodies from fat metabolism compete with uric acid for renal excretion. The combination temporarily raises serum uric acid above the crystallization threshold.

How much weight loss is safe to avoid gout flares?

Weight loss of 1% or less of body weight per week is generally safe. Faster loss (2% or more per week) increases flare risk. The early phase of GLP-1 treatment often exceeds this threshold, which is why prophylaxis is recommended for high-risk patients.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
4. Yamashita S et al. Effects of Weight Loss on Serum Uric Acid Levels. Obesity. 2019.
5. Chen L et al. Gout Flares During GLP-1 Receptor Agonist Therapy: A Retrospective Cohort Study. Arthritis & Rheumatology. 2024.
6. Liu Y et al. Effects of GLP-1 Receptor Agonists on Serum Uric Acid: A Meta-Analysis. Diabetes, Obesity and Metabolism. 2023.
7. Stamp LK et al. The Effect of Weight Loss on Gout Flare Frequency. Annals of the Rheumatic Diseases. 2013.
8. Blonde L et al. Real-World Outcomes with Semaglutide 2.4 mg for Weight Management. Diabetes Care. 2023.
9. Davies MJ et al. Gastric Emptying and Metabolic Effects of Tirzepatide. Diabetes Care. 2023.
10. Neogi T et al. 2015 Gout Classification Criteria. Arthritis & Rheumatology. 2015.
11. FitzGerald JD et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis & Rheumatology. 2020.
12. Richette P et al. 2016 Updated EULAR Evidence-Based Recommendations for the Management of Gout. Annals of the Rheumatic Diseases. 2017.
13. Khanna D et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Arthritis Care & Research. 2012.
14. Dalbeth N et al. Gout. The Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.